Blog

Mindset Pharma Inc. (CSE: MSET | FSE: 9DF | OTCQB: MSSTF), a drug discovery company developing novel, optimized, next-generation psychedelic and non-psychedelic medications to treat neuropsychiatric and neurological disorders with unmet medical needs, today announced upcoming poster presentations related to its second-generation psilocybin-like lead drug candidate, MSP-1014 at two upcoming scientific conferences. The poster presentations compare a novel prodrug of psilocin, MSP-1014, to psilocybin in preclinical studies evaluating safety, behavioral and pharmacokinetics properties of both psilocin prodrugs. In addition, collaborative work will be presented on benchmarking psilocybin in various animal models. 5th Annual Neuropsychiatric & Psychedelics Drug Development SummitLocation: Boston, MATitles: “The Preclinical Safety,…

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced the launch of its Ketamine for Chronic and Serious Medical Illness Program. This new program will be introduced first in Numinus’ clinics in Utah, British Columbia and Quebec. The Company intends to expand the program to other clinics in later months. “Chronic and serious medical illness encompasses a wide range of diagnoses, from terminal cancer to chronic pain. In the US alone, six million people could benefit from palliative care, but current treatments have gaps that leave patients struggling to cope with distress. Numinus’ program addresses…

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2022, and provide an update on recent business developments on 3 November 2022. The management team will host a conference call at 8:00am ET (1:00pm UK) on 3 November. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on COMPASS Pathway’s website at: Third Quarter 2022 Financial Results. The…

HAVN Life Sciences Inc. (CSE: HAVN | OTC: HAVLF | FSE: 5NP), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural health products, is pleased to announce that it has secured a product listing with Canada’s largest grocery retailer, Loblaws Company Ltd (LCL) for the Company’s line of natural health products. Havn Life previously had secured distribution in all 23 Ontario locations of Loblaws’ Fortinos banner in July 2022.  LCL has now approved expansion of HAVN’s products across Canada. The Canadian-owned and operated supermarket chain will carry 6 of the 11 HAVN Life natural health products nationally in store banners…

Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced it will sponsor and participate in Wonderland, the World’s Leading Psychedelic Event, organized by Microdose Psychedelics Insights, to be held at the Mana Wynwood Convention Center in Miami, FL from November 3rd to the 5th Seelos will sponsor the Press Breakfast with Seelos Therapeutics on Friday November 4th at 8:30am ET to discuss their SLS-002 (intranasal racemic ketamine) program, which is currently enrolling patients in Part 2 of the registration directed, randomized, double-blind, placebo-controlled clinical study. The purpose of the study is to evaluate the efficacy, safety, and…